Section Arrow
MLYS.NASDAQ
- Mineralys Therapeutics
Quotes are at least 15-min delayed:2026/01/09 19:35 EST
After Hours
Last
 33.92
+0.55 (+1.65%)
Bid
33.37
Ask
33.92
High 33.92 
Low 33.17 
Volume 10.34K 
Regular Hours (Closed)
Last
 33.37
+0.24 (+0.72%)
Day High 
33.92 
Prev. Close
33.13 
1-M High
39.15 
Volume 
1.36M 
Bid
33.37
Ask
33.92
Day Low
32.71 
Open
33.27 
1-M Low
32.61 
Market Cap 
2.62B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 35.88 
20-SMA 36.29 
50-SMA 39.25 
52-W High 47.65 
52-W Low 8.241 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.92/-2.30
Enterprise Value
2.62B
Balance Sheet
Book Value Per Share
7.28
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
MREOMereo BioPharma Group plc0.4944+0.11+28.62%-- 
After Hours 0.4906 -0.0038 -0.77%
ASBPAspire Biopharma Holdings Inc.0.104+0.0007+0.68%-- 
After Hours 0.1003 -0.0037 -3.56%
RVMDRevolution Medicines118.64+11.25+10.48%-- 
After Hours 118.65 +0.01 +0.01%
ARDXArdelyx7.74+0.74+10.57%-- 
After Hours 7.81 +0.07 +0.90%
SLSSELLAS Life Sciences Group3.46-0.4-10.36%-- 
After Hours 3.49 +0.03 +0.87%
Industry overview quotes are at least 15 minutes delayed
Business Description
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two ormore lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.